{"page":{"totalFilteredElements":80},"studies":[{"active":true,"description":"

 Surgery as\nneeded versus surgery on principle in patients with postneoadjuvant\nclinical complete tumor response of esophageal\ncancer - ESORES-Trial 

DRKS00022801

","eudractNumber":null,"id":10294,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-10-15T09:16:00+02:00","shortTitle":"ESORES","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A multinational registry for rhabdoid tumors of any anatomical site / EU-RHAB-Register (AT/RT)","eudractNumber":null,"id":232,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2010-11-15T10:59:53+01:00","shortTitle":"EU-RHAB","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Prospective non-randomized multi-center study for epidemiology and characterization of MDS and JMML in childhood
ICD-10: C93.3
","eudractNumber":null,"id":133,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT00662090","phase":null,"recruitmentStart":"2006-04-19T10:30:21+02:00","shortTitle":"EWOG-MDS 2006","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"

EWOG - SAA 2010

Genetische und immunologische Charakterisierung der erworbenen schweren aplastischen Anämie (SAA) bei Kindern und Jugendlichen

","eudractNumber":null,"id":1772,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2012-10-30T10:30:42+01:00","shortTitle":"EWOG-SAA 2010","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Fanconi Anemia Registry 01","eudractNumber":null,"id":2355,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[{"name":"FANC (Fanconi anemia complementation group)","id":"mt_21"}],"nctNumber":null,"phase":null,"recruitmentStart":"2014-01-01T08:34:26+01:00","shortTitle":"Fanconi Anämie Register (FAR01)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Eine offene, forschungsinitiierte Phase I/II – Studie mit Venetoclax in Kombination mit Blinatumomab Immuntherapie bei erwachsenen Patienten mit rezidivierter/refraktärer ALL","eudractNumber":"2021-001384-25","id":9997,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD19","id":"mt_55"}],"nctNumber":"NCT05182385","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2022-02-14T12:14:09+01:00","shortTitle":"GMALL-BLIVEN","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"GPOH HD Study Registry 2.0
Prospective Registry for children and adolescents with classical Hodgkin Lymphoma, nodular lymphocyte-predominant Hodgkin Lymphoma and relapsed Hodgkin Lymphoma

","eudractNumber":null,"id":10077,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped2","name":"Lymphome"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2024-10-07T09:34:03+02:00","shortTitle":"GPOH HD Study Registry 2.0","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"International HIT-MED Registry: For children, adolescents, and adults \nwith medulloblastoma, ependymoma, pineoblastoma, CNS-primitive \nneuroectodermal tumours","eudractNumber":null,"id":1592,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT02417324","phase":null,"recruitmentStart":"2015-01-01T11:20:20+01:00","shortTitle":"I-HIT MED Registry","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE)
","eudractNumber":"2021-000330-33","id":6920,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym2","name":"Morbus Hodgkin"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT04837859","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-12-06T13:28:10+01:00","shortTitle":"INDIE","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)","eudractNumber":"2023-505306-42","id":9869,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[{"name":"BRAF","id":"mt_9"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF V600","id":"mt_5"},{"name":"HLA (Humane Leukozytenantigene)","id":"mt_174"}],"nctNumber":"NCT06112314","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-06T09:44:34+01:00","shortTitle":"Immunocore IMC-F106C-301","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}